HYPERICUM

Chronic Pain

Uriach Consumer HealthcaremixtureN/ADormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 73/ 100

Competitive context

80 Active assets in the Chronic Pain cohort.

Asset / Sponsor	Phase	Rating
(±)-TRAMADOL EMS	Phase 4	BBB
LIDOCAINE National and Kapodistrian University of Athens	Phase 4	BBB
NEPENTHE Bursa City Hospital	Phase 4	BBB
FENTANYL Aga Khan University	Phase 4	BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Stanford University	Phase 4	BBB

View all 50 →

Same molecule, other indications

HYPERICUM is also rated in:

urinary system neoplasmDormant

B

Indicative ·

59 / 100

male reproductive organ cancerDormant

B

Indicative ·

59 / 100

thoracic cancerDormant

B

Indicative ·

59 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.